Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Omicron Variant: Effects on Treatments for COVID-19

Do COVID-19 treatments retain their efficacy against the SARS-CoV-2 omicron variant? Hear expert faculty discuss the use of direct-acting, small-molecule antiviral agents and monoclonal antibodies during the omicron era.
Arthur Kim, MD
Released: January 25, 2022

The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:

  • Direct-acting, small-molecule antiviral agents such as   molnupiravir, nirmatrelvir + ritonavir, and remdesivir
  • Monoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimab

Information on this Educational Activity


Arthur Kim, MD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he has served on the scientific advisory board for Kintor and served as a NIH-funded site-investigator for a prevention trial for casirivimab/imdevimab.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.

Related Content

Expert faculty provide a comprehensive overview of current landscape of outpatient COVID-19 management strategies, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE

Renslow Sherer, MD person default Trinh P. Vu, PharmD, BCIDP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 22, 2022 Expired: November 21, 2023

Dr Jason Gallagher and Dr Emily Heil on COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound, from Clinical Care Options (CCO)

person default Jason Gallagher, PharmD Emily Heil, PharmD, MS, BCIDP, AAHIVP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: November 22, 2022 Expired: November 21, 2023

Clinical Care Options (CCO) podcast with Dr Princy N. Kumar and Dr Paul E. Sax on key COVID-19 data from IDWeek 2022

Princy N. Kumar, MD, FIDSA, MACP Paul E. Sax, MD Released: November 18, 2022

Dr Gregory Huhn discusses new COVID-19 data from IDWeek 2022 on severe breakthrough infection risk and antiviral treatment, from Clinical Care Options (CCO)

Gregory Huhn, MD, MPHTM Released: November 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings